Steward Health Care System

Return to Results

A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers

new search

Trial Conditions
  • Cervical Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Vaginal Cancer
  • Carcinoma of the Vulva
What is the purpose of this trial?

This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e. endometrial, cervical, vulvar, ovarian or vaginal cancers).

Date & Status

Active, not recruiting

Who can Participate?

Eligibility

Ages:
18 and older

Gender:
Female

Eligibility

Inclusion Criteria:

- All patients (age > 18 years) will have locally recurrent gynecological cancer with a
component of disease that will fit within a standard RT portal at the time of
presentation

- ECOG performance status score 0-1

- All patients will have had a prior hysterectomy

- Histological confirmation of recurrent gynecological cancer, including
adenocarcinoma, papillary serous carcinoma, clear cell carcinoma, or carcinosarcoma

- Age > 18 years

- Radiologic work-up computer tomography of the chest and abdomen, and computer
tomography or MR of the pelvis confirming pelvis-confined recurrence

- Adequate renal function as evidenced by serum creatinine < 1.5 mg/dL

- Adequate hepatic function as evidenced by:

Serum total bilirubin < 1.5 mg/dL SGOT/SGPT < 3X the ULN for the reference lab

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients with a prior history of full course external beam radiation therapy to the
pelvis (patients with prior vaginal brachytherapy may be included)

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 12 weeks

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored avastin
cancer study

- Known CNS disease (including history of encephalitis, multiple sclerosis or seizure
disorder), except for treated brain metastasis

- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or
diastolic blood pressure > 100 mmHg on antihypertensive medications)

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Known CNS disease (including history of encephalitis, multiple sclerosis or seizure
disorder)

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Any surgical procedure requiring an incision, open biopsy, or significant traumatic
injury within 28 days prior to study enrollment or anticipation of need for any
surgical procedure requiring an incision during the course of the study (excluding
vascular access device placement or procedures that do not require an incision)

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening as demonstrated by either Urine protein:creatinine (UPC)
ratio ≥ 1.0 at screening OR Urine dipstick for proteinuria ≥ 2+ (patients discovered
to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour
urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).

- Known hypersensitivity to any component of avastin

- Any other medical condition, including mental illness or substance abuse, deemed by
the Investigator to be likely to interfere with a patient's ability to give informed
consent or cooperate and participate in the study or to interfere with the
investigator's ability to interpret the results

Gender: Female
Steward Physician(s)
  • Akila N Viswanathan, MD, MPH
Trial Interventions
Drug
  • Avastin
Physician Researcher

Investigator Name:

  • Akila N Viswanathan, MD, MPH

Other Information

Sponsor: Dana-Farber Cancer Institute
Phase: Phase 2
Trial ID: NCT00545792
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions